Meta-Analysis of Ezacib and Atorvastatin on Chinese Patients with Coronary Heart Disease

Objective To evaluate the efficacy and safety of Ezetimibe combined with Atorvastatin and Atorvastatin alone in patients with coronary heart disease （CHD） in China. Methods EMBASE, PubMed, CNKI, CBM and Wanfang database were used to search the data of Chinese patients with CHD who were treated with Ezetimibe and Atorvastatin alone. Randomized controlled trials （RCTs） comparing the efficacy and safety of statin treatment with Atorvastatin and meta-analysis using RevMan5.3 software. Results A total of 1 490 patients were enrolled in 13 RCTs. Meta-analysis showed that major improvement in combination group with in aspect of low-density lipoprotein cholesterol （LDL-C） （MD=-0.67,95%CI -0.83~-0.51, P<0.05）, total cholesterol （TC） （MD=-0.90,95%CI -1.09~-0.71, P<0.05）, triglyceride （TG）（MD=-0.21,95%CI -0.35~0.06,P<0.05） and The incidence of adverse reactions （myalgia: OR=0.32, 95%CI 0.13~0.79, P<0.05; the incidence of gastrointestinal reactions: OR=0.36,95%CI 0.17~0.79, P<0.05）. The clinical effect （OR=3.53,95%CI 2.21~5.65, P<0.05） increased significantly. Conclusion The use of Ezetimibe and Atorvastatin in CHD patients in China can significantly reduce the incidence of adverse reactions and blood lipid levels in patients with CHD.